Daily Ards Research Analysis
Analyzed 10 papers and selected 3 impactful papers.
Summary
Analyzed 10 papers and selected 3 impactful articles.
Selected Articles
1. Effects of Protective Ventilation with Lung Expansion versus Permissive Atelectasis on Pulmonary Inflammation and Mechanical Power of Ventilation in an Experimental Model of Acute Lung Injury.
In a randomized porcine acute lung injury model, individualized higher PEEP strategies targeting lung expansion reduced pulmonary FDG uptake (ΔKiS) and mechanical power versus permissive atelectasis. Mechanical power correlated with inflammatory activity, reinforcing its mechanistic link to ventilator-induced lung injury.
Impact: This study quantitatively links ventilator mechanical power to pulmonary inflammation and demonstrates benefits of individualized higher PEEP in a controlled experimental setting.
Clinical Implications: While preclinical, the findings support prioritizing individualized PEEP titration to minimize mechanical power and inflammation rather than accepting permissive atelectasis, informing trial design and bedside strategies.
Key Findings
- ΔKiS was higher with LowPEEP than OLA (0.0183±0.0109 vs. 0.0049±0.0088 min−1; P=0.024).
- Mechanical power was higher with LowPEEP [9.5 J/min] than HighPEEP [7.5 J/min; P=0.008] and OLA [6.8 J/min; P=0.002].
- Mechanical power correlated positively with ΔKiS across groups (ρ=0.425, P=0.038).
- Inflammation (ΔKiS) did not significantly differ between HighPEEP and OLA (P=0.876).
Methodological Strengths
- Randomized allocation to three predefined ventilatory strategies with standardized protocols.
- Quantitative inflammation assessment via FDG-PET (KiS) paired with mechanical power derivation from pressure-volume curves.
Limitations
- Preclinical porcine model with small sample size (n=24) limits generalizability.
- Short 24-hour observation without long-term outcomes or blinded assessments.
Future Directions: Prospective human trials should test individualized PEEP titration to reduce mechanical power and inflammation and evaluate patient-centered outcomes and safety.
BACKGROUND: The energy transferred from the mechanical ventilator to the respiratory system over time, so-called mechanical power, may cause lung injury even with protective ventilation. We hypothesized that protective ventilation aiming at moderate lung expansion results in less mechanical power and lung injury than aiming at permissive atelectasis or maximum lung expansion. METHODS: Twenty-four anesthetized pigs with acute lung injury induced by saline lung lavage were randomly assigned to ventilation according to either Acute Respiratory Distress Syndrome Clinical Network´s low positive end-expiratory pressure (PEEP) table (LowPEEP), or high PEEP table (HighPEEP), or Open Lung Approach with PEEP titrated to the highest respiratory system compliance and periodic recruitment maneuvers (OLA) (n=8/group). Mechanical power was calculated from pressure-volume curves, and physiological variables were measured. We assessed pulmonary inflammation as the tissue-normalized uptake rate of 2-deoxy-2-[18F]fluoro-D-glucose measured by positron-emission computed tomography (KiS) and determined the gradient between randomization and 24h thereafter (∆KiS). RESULTS: The median (IQR) PEEP was 5(0.1), 12(0.2), and 12(0.2) cmH2O during LowPEEP, HighPEEP, and OLA, respectively. ΔKiS was higher in LowPEEP than OLA (0.0183±0.0109 vs. 0.0049±0.0088 min-1; P=0.024; d=0.47), but did not differ significantly from HighPEEP (0.0080±0.0073 min-1; P=0.104; d=0.85). ΔKiS also did not differ between HighPEEP and OLA (P=0.876; d=0.60). The median (IQR) mechanical power in LowPEEP [9.5(1.5) J/min] was higher than in HighPEEP [7.5(2.3) J/min; P=0.008; d=4.28] and OLA [6.8(2.1) J/min; P=0.002; d=4.69], but did not statistically differ between HighPEEP and OLA (P=0.886; d=0.199). Mechanical power correlated positively with ΔKiS across groups (ρ=0.425, P=0.038). CONCLUSIONS: In this porcine model of acute lung injury, protective ventilation with individualized higher PEEP aiming at lung expansion resulted in less pulmonary inflammation and lower mechanical power compared to protective ventilation with permissive atelectasis. A strategy with higher PEEP but without individualization did not differ significantly from the other two strategies regarding inflammation.
2. Association of glucose-lymphocyte ratio and short-term mortality in patients with sepsis complicated by ARDS during the acute phase: a multicenter retrospective cohort study.
In 2,485 derivation and 298 validation patients with sepsis-induced ARDS, higher admission GLR independently predicted 28-day mortality, with a linear risk gradient. GLR improved discrimination over APS III and SAPS II and was most informative in those without severe liver disease or extreme physiologic derangement.
Impact: Introduces a simple, readily available biomarker with external validation for early mortality risk stratification in sepsis-induced ARDS.
Clinical Implications: GLR can augment existing severity scores to triage sepsis-induced ARDS patients, prioritize monitoring and resources, and inform trial enrichment—especially where liver dysfunction is absent.
Key Findings
- Each unit increase in GLR was associated with higher 28-day mortality (adjusted HR 1.13; 95% CI 1.053–1.211; P<0.001).
- Results were replicated in an external validation cohort (n=298).
- Risk increased linearly with GLR (RCS), but predictive value attenuated with high SAPS II (>40), APS III (>53), or severe liver disease.
- Adding GLR improved AUCs for APS III (0.694→0.708) and SAPS II (0.678→0.696).
Methodological Strengths
- Large multicenter derivation with external validation.
- Robust modeling (multivariable Cox, LASSO-Boruta), nonlinearity assessment (RCS), and clinical utility analyses (ROC, DCA).
Limitations
- Retrospective design with potential residual confounding and selection bias.
- Attenuated performance in high-severity or severe liver disease populations; generalizability beyond included centers remains to be tested.
Future Directions: Prospective multicenter validation, exploration of GLR trajectories, and evaluation of whether GLR-guided management improves outcomes.
BACKGROUND: Sepsis may precipitate acute respiratory distress syndrome (ARDS), a life-threatening pulmonary complication characterized by high mortality. The glucose-to-lymphocyte ratio (GLR) is a novel composite biomarker has demonstrated prognostic significance across multiple diseases. However, its association with short-term mortality in patients with sepsis-induced ARDS has not yet been clearly established. METHODS: In this multicenter retrospective cohort analysis, data from 2,485 individuals in the MIMIC-IV database were used to construct the primary derivation cohort, while an additional set of 298 patients from the Affiliated Hospital of Xuzhou Medical University served as an independent cohort for external validation. All-cause mortality at 28 days was defined as the primary outcome of the study. Least absolute shrinkage and selection operator (LASSO)-Boruta selected predictors. We evaluated the relationship between the GLR and mortality by employing multivariable Cox proportional hazards modeling, complemented by restricted cubic spline (RCS) and subgroup analyses. Receiver operating characteristic curves (ROC) and decision curve analysis (DCA) quantified incremental value of GLR over the Acute Physiology Score III (APS III) and the Simplified Acute Physiology Score II (SAPS II). RESULTS: In the derivation cohort, higher GLR values were independently linked to an increased risk of 28-day mortality (adjusted HR 1.13 per unit increase, 95% CI: 1.053-1.211, P < 0.001). The finding was replicated in the external validation cohort. Short-term mortality increased linearly with rising GLR levels, as shown by RCS analysis. Subgroup analyses identified significant interactions: the prognostic value of GLR was significantly attenuated or lost in patients with high illness severity scores (SAPS II > 40, APS III > 53) or severe liver disease, while it remained robust in patients with lower severity scores and without severe liver disease. Incorporating GLR into APS III and SAPS II models improved their AUC values (APS III: 0.694 vs. 0.708; SAPS II: 0.678 vs. 0.696). CONCLUSIONS: An elevated GLR at admission independently predicts 28-day mortality in patients with sepsis-induced ARDS. This marker is especially useful for early risk stratification among patients without advanced liver dysfunction or severe physiological abnormalities.
3. Evaluation of Neuromuscular Blocking Agent Utilization in Extracorporeal Membrane Oxygenation.
In a single-center ECMO cohort, about half of patients received NMBs—mostly rocuronium boluses—with continuous infusions used infrequently. When administered for hypoxemia or low ECMO flows, NMBs were associated with improved PaO2 and circuit flow at 1 hour, with low documented neuromuscular dysfunction.
Impact: Provides contemporary, granular practice data on NMB use during ECMO with quantified short-term physiologic benefits, informing bedside decision-making.
Clinical Implications: Clinicians can consider targeted, short-term NMB for hypoxemia or low ECMO flows to improve oxygenation and flow, while minimizing continuous infusions and monitoring for neuromuscular dysfunction.
Key Findings
- Approximately 50% of ECMO patients received NMBs; most were rocuronium boluses, with continuous infusion used in 12%.
- Indications: bedside procedures (66%), hypoxemia (9%), low ECMO flows (6%).
- When used for hypoxemia, PaO2 improved from 64 to 105 mm Hg at 1 hour (p<0.001); for low ECMO flows, flow improved from 2.9 to 4.0 L/min (p=0.016).
- Documented neuromuscular dysfunction occurred in 6% of patients.
Methodological Strengths
- Large single-center ECMO experience with detailed capture of indications, dosing, and short-term physiologic responses.
- Objective pre/post comparisons at 1 hour for PaO2 and ECMO flow in relevant subgroups.
Limitations
- Retrospective single-center design with potential indication bias and unmeasured confounding.
- Short-term physiologic improvements were not linked to long-term outcomes; neuromuscular monitoring was not standardized.
Future Directions: Prospective studies should define standardized protocols for NMB use on ECMO, evaluate dose-response, safety (including ICU-acquired weakness), and effects on clinical outcomes.
Neuromuscular blocking agent (NMB) utilization has been infrequently described in patients requiring extracorporeal membrane oxygenation (ECMO). The goal of this analysis was to evaluate NMB utilization at a high-volume ECMO center. This was a retrospective cohort study of patients who required ECMO at the Cleveland Clinic between January 2022 and December 2023. NMB utilization was collected, including the agent, dose, duration (if continuous infusion), and indication. Other clinical outcomes recorded included duration of ECMO support, evidence of neuromuscular dysfunction, and hospital mortality. In total, 329 patients were evaluated, and 280 patients were included. Nearly 50% of patients received NMB during their ECMO course. Most utilization was rocuronium bolus. Continuous infusion NMB was only used in 12%. Common indications for NMB were for bedside procedures (66%), hypoxemia (9%), and ECMO low flows (6%). When used for hypoxemia or ECMO low flows, administration of NMB was associated with an improvement in partial pressure of arterial oxygen (PaO2) (64 vs. 105 mm Hg, p < 0.001) and ECMO flow (2.9 vs. 4.0 L/min, p = 0.016) at 1 hour, respectively. Evidence of neuromuscular dysfunction was documented in 6% of patients. Neuromuscular blocking agent use was needed in about half of patients on ECMO, but few patients required continuous NMB.